Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients

New England Journal of Medicine

Volumn 338, Issue 20, 1998, Pages 1413-1421

  Liebowitz, David ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BURKITT LYMPHOMA; EPSTEIN BARR VIRUS; HUMAN; IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE MICROSCOPY; LYMPHOMA; MALIGNANT TRANSFORMATION; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; GENE EXPRESSION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOMA, NON-HODGKIN; LYMPHOPROLIFERATIVE DISORDERS; MICROSCOPY, FLUORESCENCE; NF-KAPPA B; PROTEINS; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 1; TNF RECEPTOR-ASSOCIATED FACTOR 3; TRANSPLANTATION; VIRAL MATRIX PROTEINS;

EID: 0032516250     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199805143382003     Document Type: Article

References (22)

1. Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. 3rd ed. Vol. 2. Philadelphia: Lippincott-Raven, 1996:2343-96.
2. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831-40.
3. Idem. The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts. J Virol 1988;62:2337-46.
4. Baichwal VR, Sugden B. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 1988;2:461-7.
5. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990; 344:777-80.
6. Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 1990;61: 1315-27.
7. Fahraeus R, Rymo L, Rhim JS, Klein G. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 1990;345:447-9.
8. Wang D, Liebowitz D, Wang F, et al. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 1988;62:4173-84.
9. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-15.
10. Hammarskjold ML, Simurda MC. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity. J Virol 1992;66: 6496-501.
11. Laherry CD, Hu HM, Opipari AW, Wang F, Dixit VM. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 1992;267:24157-60.
12. Rowe M, Peng-Pilon M, Huen DS, et al. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. J Virol 1994;68:5602-12.
13. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 1993;90:9150-4.
14. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80: 389-99.
15. Kaye KM, Devergne O, Harada JN, et al. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci U S A 1996;93:11085-90.
16. Devergne O, Hatzivassiliou E, Izumi KM, et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol Cell Biol 1996;16:7098-108.
17. Liebowitz D, Mannick J, Takada K, Kieff E. Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells. J Virol 1992;66:4612-6.
18. Liebowitz D, Kieff E. Epstein-Barr virus. In: Roizman B, Whitley RJ, Lopez C, eds. The human herpesviruses. New York: Raven Press, 1993: 107-72.
19. Rowe DT, Rowe M, Evan GI, Wallace LE, Farrell PJ, Rickinson AB. Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J 1986;5:2599-607.
20. Hatzubai A, Anafi M, Masucci MG, et al. Down-regulation of the EBV-encoded membrane protein (LMP) in Burkitt lymphomas. Int J Cancer 1987;40:358-64.
21. Gregory CD, Rowe M, Rickinson AB. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol 1990;71:1481-95.
22. Liebowitz D, LeBeau MM, Olopade OI. Evidence for signal transduction through the TNF receptor pathway in post-transplant lymphoproliferative disorders. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14: A51. abstract.